The Biologics News and Reports Portal

Show Cart

Target Pipelines

Results 31 - 40 of 67

Jun 2018 Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin

810.00 €

1,350.00 €

(Discount: 40.00%)

Jun 2018 Competitor Analysis: MAGE-A-Targeted Immunotherapy

150.00 €

Jun 2018 Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

400.00 €

Jun 2018 Competitor Analysis: hTERT-Targeted Immunotherapy

150.00 €

Jun 2018 Competitor Analysis: WT1-Targeted Immunotherapy

300.00 €

Jun 2018 Competitor Analysis: PRAME-Targeted Immunotherapy

150.00 €

May 2018 Competitor Analysis: Survivin-Targeted Immunotherapy

200.00 €

Shopping cart

Cart empty

Latest report

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Featured Products

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Report bundle: Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Shopping cart

Cart empty

Latest report

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Featured Products

Report bundle: Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Target Pipelines

Jul 2018 CTLA-4 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 LAG-3 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 TIM-3 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jun 2018 Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin

Jun 2018 Competitor Analysis: MAGE-A-Targeted Immunotherapy

Jun 2018 Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

Jun 2018 Competitor Analysis: hTERT-Targeted Immunotherapy

Jun 2018 Competitor Analysis: WT1-Targeted Immunotherapy

Jun 2018 Competitor Analysis: PRAME-Targeted Immunotherapy

May 2018 Competitor Analysis: Survivin-Targeted Immunotherapy

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing